Silence Therapeutics PLC Sponsored ADR
Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.
Follow SLN
Silence Therapeutics PLC Sponsored ADR (SLN) EV/Sales
As of 16 October 2026, Silence Therapeutics PLC Sponsored ADR (SLN) trades at a EV/Sales of 403×. Over the past ten years it has ranged from −1.2× (April 2025) to 783× (August 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 362× | 9,047.51% |
| FY2024 | 4.0× | (79.80%) |
| FY2023 | 19.6× | 10.07% |
| FY2022 | 17.8× | 7.78% |
| FY2021 | 16.5× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 213× | (41.03%) |
| Dec 2025 | 362× | 6,427.83% |
| Sep 2025 | 5.5× | (5.89%) |
| Jun 2025 | 5.9× | — |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| CRMD CorMedix Inc compare | 1.0× |
| PHAT Phathom Pharmaceuticals, Inc. compare | 2.4× |
| ZVRA Zevra Therapeutics, Inc. compare | 3.4× |
| VALN Valneva SE Sponsored ADR compare | 3.5× |
| STTK Shattuck Labs, Inc. compare | 88.3× |
| DBVT DBV Technologies S.A. compare | 124× |
| SLN Silence Therapeutics PLC Sponsored ADR | 403× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)